Savara (SVRA) Competitors $2.13 +0.04 (+1.67%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$2.19 +0.06 (+2.81%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SVRA vs. EVO, OCUL, GRDN, AUPH, HROW, DYN, ELVN, VERV, COLL, and AKBAShould you be buying Savara stock or one of its competitors? The main competitors of Savara include Evotec (EVO), Ocular Therapeutix (OCUL), Guardian Pharmacy Services (GRDN), Aurinia Pharmaceuticals (AUPH), Harrow (HROW), Dyne Therapeutics (DYN), Enliven Therapeutics (ELVN), Verve Therapeutics (VERV), Collegium Pharmaceutical (COLL), and Akebia Therapeutics (AKBA). These companies are all part of the "med - drugs" industry. Savara vs. Its Competitors Evotec Ocular Therapeutix Guardian Pharmacy Services Aurinia Pharmaceuticals Harrow Dyne Therapeutics Enliven Therapeutics Verve Therapeutics Collegium Pharmaceutical Akebia Therapeutics Evotec (NASDAQ:EVO) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, media sentiment, earnings and analyst recommendations. Does the media prefer EVO or SVRA? In the previous week, Evotec had 1 more articles in the media than Savara. MarketBeat recorded 2 mentions for Evotec and 1 mentions for Savara. Evotec's average media sentiment score of 1.13 beat Savara's score of 0.00 indicating that Evotec is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Evotec 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Savara 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Is EVO or SVRA more profitable? Savara has a net margin of 0.00% compared to Evotec's net margin of -26.34%. Evotec's return on equity of -21.51% beat Savara's return on equity.Company Net Margins Return on Equity Return on Assets Evotec-26.34% -21.51% -10.54% Savara N/A -65.88%-52.35% Do institutionals & insiders believe in EVO or SVRA? 5.8% of Evotec shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 1.0% of Evotec shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, EVO or SVRA? Savara has lower revenue, but higher earnings than Evotec. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvotec$862.40M1.73-$212.18MN/AN/ASavaraN/AN/A-$95.88M-$0.48-4.45 Which has more volatility & risk, EVO or SVRA? Evotec has a beta of 1.66, meaning that its share price is 66% more volatile than the S&P 500. Comparatively, Savara has a beta of 0.31, meaning that its share price is 69% less volatile than the S&P 500. Do analysts prefer EVO or SVRA? Evotec presently has a consensus target price of $5.93, indicating a potential upside of 41.44%. Savara has a consensus target price of $5.60, indicating a potential upside of 162.30%. Given Savara's stronger consensus rating and higher probable upside, analysts clearly believe Savara is more favorable than Evotec.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evotec 0 Sell rating(s) 3 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.40Savara 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.60 SummarySavara beats Evotec on 7 of the 13 factors compared between the two stocks. Get Savara News Delivered to You Automatically Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SVRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVRA vs. The Competition Export to ExcelMetricSavaraMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$378.51M$2.43B$5.56B$9.04BDividend YieldN/A1.78%5.24%4.01%P/E Ratio-4.459.1027.6120.24Price / SalesN/A680.45417.30118.22Price / CashN/A158.5936.8958.10Price / Book2.144.588.035.67Net Income-$95.88M$31.34M$3.18B$249.21M7 Day Performance-3.39%3.25%2.93%3.28%1 Month Performance-10.29%7.08%3.75%5.55%1 Year Performance-51.81%0.17%35.20%21.09% Savara Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVRASavara1.8028 of 5 stars$2.14+1.7%$5.60+162.3%-50.7%$378.51MN/A-4.45N/AGap UpEVOEvotec1.7188 of 5 stars$4.20+1.0%$5.93+41.3%-18.5%$1.48B$862.40M0.004,827News CoveragePositive NewsOCULOcular Therapeutix3.9648 of 5 stars$9.28+0.7%$17.33+86.8%+39.9%$1.47B$63.72M0.00230Positive NewsGRDNGuardian Pharmacy Services1.4024 of 5 stars$21.39+0.0%$25.67+20.0%N/A$1.35B$1.23B0.003,400High Trading VolumeAUPHAurinia Pharmaceuticals3.0923 of 5 stars$8.47-2.0%$11.50+35.8%+38.3%$1.17B$235.13M23.35300HROWHarrow2.698 of 5 stars$30.54-1.1%$61.40+101.0%+47.1%$1.13B$199.61M0.00182Positive NewsDYNDyne Therapeutics3.5007 of 5 stars$9.52-0.5%$41.13+332.0%-73.5%$1.09BN/A0.00100ELVNEnliven Therapeutics2.5077 of 5 stars$20.06-3.0%$39.60+97.4%-4.1%$1.01BN/A0.0050Analyst ForecastAnalyst RevisionVERVVerve Therapeutics3.4317 of 5 stars$11.23-0.6%$14.57+29.8%+118.4%$1.01B$32.33M0.00110COLLCollegium Pharmaceutical4.1132 of 5 stars$29.57-1.2%$43.75+48.0%-6.1%$961.71M$631.45M5.19210News CoverageAnalyst DowngradeAKBAAkebia Therapeutics4.2576 of 5 stars$3.64-0.3%$6.75+85.4%+280.9%$958.62M$160.18M0.00430Insider Trade Related Companies and Tools Related Companies EVO Alternatives OCUL Alternatives GRDN Alternatives AUPH Alternatives HROW Alternatives DYN Alternatives ELVN Alternatives VERV Alternatives COLL Alternatives AKBA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SVRA) was last updated on 7/5/2025 by MarketBeat.com Staff From Our PartnersA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredThe #1 AI Energy StockNearly $600 billion is projected to be spent on AI data centers this year. That's because the ones being bu...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SVRA Stock Alerts